Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2008

01.11.2008 | Original Paper

Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor

verfasst von: Parvin Mehdipour, Laleh Habibi, Javad Mohammadi-Asl, Naser Kamalian, Masoud Mehr Azin

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Ataxia telangictasia mutated (ATM) is involved in DNA repair pathway and cell-cycle checkpoints. ATM alterations were found in medulloblastomas, gliomas, but not in astrocytoma. The polymorphism D1853N was reported in healthy individuals and medulloblastomas. We could observe this polymorphism, heterozygously, in a proband affected with astrocytoma and traced it through her pedigree. We propose the three-hit hypothesis as a triangle initiators includes D1853N as a first predisposing hit, IVS 38- 63T → A as a second hit deriving from the first somatic evolution before differentiation and IVS 38- 30 A → G as a third hit through the development of an astrocytoma. In addition, the D1853N polymorphism was occurred in different allele from IVS 38- 63T → A and IVS 38- 30 A → G.
Literatur
Zurück zum Zitat Bigbee WL, Langlois RG, Swift, Jensen RH (1989) Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. Am J Hum Genet 44(3):402–408 Bigbee WL, Langlois RG, Swift, Jensen RH (1989) Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. Am J Hum Genet 44(3):402–408
Zurück zum Zitat Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K (1991) Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 70(2):99–117PubMedCrossRef Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K (1991) Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 70(2):99–117PubMedCrossRef
Zurück zum Zitat Haerer AF, Jackson JF, Evers CG (1969) Ataxia-telangiectasia with gastric adenocarcinoma. JAMA 210(10):1884–1887PubMedCrossRef Haerer AF, Jackson JF, Evers CG (1969) Ataxia-telangiectasia with gastric adenocarcinoma. JAMA 210(10):1884–1887PubMedCrossRef
Zurück zum Zitat Hecht F, Koler RD, Rigas DA, Dahnke GS, Case MP, Tisdale V, Miller RW (1966) Leukemia and lymphocytes in ataxia-telangiectasia. Lancet II:1193 Hecht F, Koler RD, Rigas DA, Dahnke GS, Case MP, Tisdale V, Miller RW (1966) Leukemia and lymphocytes in ataxia-telangiectasia. Lancet II:1193
Zurück zum Zitat Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820–823PubMedCrossRef Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820–823PubMedCrossRef
Zurück zum Zitat Liberzon E, Avigada S, Cohen IJ, Yaniv I, Michovitz Sh, Zaizov R (2003) ATM gene mutations are not involved in medulloblastoma in children. Cancer Genet Cytogenet 146(2):167–169PubMedCrossRef Liberzon E, Avigada S, Cohen IJ, Yaniv I, Michovitz Sh, Zaizov R (2003) ATM gene mutations are not involved in medulloblastoma in children. Cancer Genet Cytogenet 146(2):167–169PubMedCrossRef
Zurück zum Zitat Matsuka S, Huang M, Elledge SJ (1989) Linkage of ATM to cell cycle regulation by the ChK2 protein kinase. Science 282:1893–1897CrossRef Matsuka S, Huang M, Elledge SJ (1989) Linkage of ATM to cell cycle regulation by the ChK2 protein kinase. Science 282:1893–1897CrossRef
Zurück zum Zitat Rosen FS, Harris NL (1987) Case records of the Massachusetts General Hospital: a 30-year-old man with ataxia-telangiectasia and dysphagia. New Eng J Med 316(2):91–100 Rosen FS, Harris NL (1987) Case records of the Massachusetts General Hospital: a 30-year-old man with ataxia-telangiectasia and dysphagia. New Eng J Med 316(2):91–100
Zurück zum Zitat Sandoval N, Platzer M, Rosenthal A, Dork T, Bendix R, Skawran B, Stuhrmann M, Wegner RD, Sperling K, Banin S, Shiloh Y, Baumer A, Bernthaler U, Sennefelder H, Brohm M, Weber BH, Schindler D (1999) Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet 8(1):69–79PubMedCrossRef Sandoval N, Platzer M, Rosenthal A, Dork T, Bendix R, Skawran B, Stuhrmann M, Wegner RD, Sperling K, Banin S, Shiloh Y, Baumer A, Bernthaler U, Sennefelder H, Brohm M, Weber BH, Schindler D (1999) Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet 8(1):69–79PubMedCrossRef
Zurück zum Zitat Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Pantanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y (1995) A single ataxia telangiectasia gene with a product similar to PI–3 kinase. Science 268:1749–1753PubMedCrossRef Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Pantanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y (1995) A single ataxia telangiectasia gene with a product similar to PI–3 kinase. Science 268:1749–1753PubMedCrossRef
Zurück zum Zitat Saxon A, Stevens RH, Golde DW (1979) Helper and suppressor T-lymphocyte leukemia in ataxia-telangiectasia. New Eng J Med 300:700–704PubMed Saxon A, Stevens RH, Golde DW (1979) Helper and suppressor T-lymphocyte leukemia in ataxia-telangiectasia. New Eng J Med 300:700–704PubMed
Zurück zum Zitat Shiloh Y (2001) ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11:71–77PubMedCrossRef Shiloh Y (2001) ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11:71–77PubMedCrossRef
Zurück zum Zitat Thorstenson YR, Shen P, Tusher VG, Wayne TL, Davis RW, Chu G, Oefner PJ (2001) Global analysis of ATM polymorphism reveals significant functional constraint. Am J Hum Genet 69(2):396–412PubMedCrossRef Thorstenson YR, Shen P, Tusher VG, Wayne TL, Davis RW, Chu G, Oefner PJ (2001) Global analysis of ATM polymorphism reveals significant functional constraint. Am J Hum Genet 69(2):396–412PubMedCrossRef
Zurück zum Zitat Tribius S, Pidel A, Casper D (2001) ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys 50(2):511–523 Tribius S, Pidel A, Casper D (2001) ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys 50(2):511–523
Zurück zum Zitat Zhang X, Li J, Sejas DP, Pang Q (2005) The ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells. J Biol Chem 280(20):19635–19640 Zhang X, Li J, Sejas DP, Pang Q (2005) The ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells. J Biol Chem 280(20):19635–19640
Metadaten
Titel
Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor
verfasst von
Parvin Mehdipour
Laleh Habibi
Javad Mohammadi-Asl
Naser Kamalian
Masoud Mehr Azin
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2008
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0404-4

Weitere Artikel der Ausgabe 11/2008

Journal of Cancer Research and Clinical Oncology 11/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.